Introduction/Overview
Cancer is one of the leading causes of death worldwide, and the exploration of its treatment strategies has always been at the core of medical research. Chemotherapy drugs have played a crucial role in the history of cancer treatment, among which compounds derived from natural products have become a treasure trove of anti-tumor drug development due to their unique chemical structures and diverse biological activities. Vinblastine sulfate (CAS: 143-67-9) is one of the shining stars. As a plant from the Apocynaceae family, Changchun flower（Catharanthus roseus）A cytotoxic indole alkaloid, vinblastine sulfate, isolated from the Chinese Academy of Sciences, has become a cornerstone drug for the treatment of various malignant tumors since it entered clinical practice in the 1960s. Its core function is to interfere with the dynamic assembly of microtubules, a crucial component of the cell cytoskeleton during mitosis, thereby blocking proliferating tumor cells in the mid division stage and ultimately inducing their apoptosis. This article aims to provide a systematic review of the chemical properties, plant sources, pharmacological activities, multidimensional mechanisms of action, pharmacological characteristics, and clinical applications of vinblastine sulfate, and to explore its future development directions.
Chemical structure and physicochemical properties
Vinblastine sulfate is the sulfate form of Vinblastine, with a molecular formula of C46H58N4O9 · H2SO4 and a molecular weight of 810.9890. From a chemical structure perspective, vinblastine is a complex macromolecular dimeric indole alkaloid formed by a complex coupling reaction between two structural units - Vindoline and Catharanthine. This dimerization structure is the basis for its high biological activity.
Its physicochemical properties profoundly affect the in vivo behavior of drugs. This compound has high lipid solubility, with a calculated LogP value of 4.1992, indicating that it is easy to penetrate cell membranes, but may also lead to poor water solubility. The measured water solubility is about 0.0240 mg/mL, which belongs to poorly soluble drugs. This usually affects their oral absorption and formulation development, and intravenous administration is commonly used in clinical practice. Its topological polar surface area (TPSA) is 154.1000 Å ², reflecting the polarity characteristics brought by multiple nitrogen and oxygen atoms in the molecule. In terms of key pharmaceutical parameters, the ability of vinblastine sulfate to penetrate the blood-brain barrier is relatively low, which limits its efficacy in treating central nervous system tumors, but may also reduce related neurotoxicity. It is gratifying that the risk of hERG inhibition is' no ', indicating a lower risk of causing QT interval prolongation and apical torsion ventricular tachycardia. In addition, the Ames test result was 0.0, indicating that there was no mutagenicity in this experimental system. However, as a strong cytotoxic drug, it still has potential genetic toxicity.
Plant sources and extraction methods
Sulfuric acid vinblastine and its analogues (such as vinblastine) are mainly derived from the plant Changchun flower（Catharanthus roseus (L.) G. Don）， Also known as Madagascar Changchun Flower. This plant is native to Madagascar and is now widely distributed in tropical and subtropical regions around the world. In plants, vinblastine is not a primary metabolite, but is synthesized through a series of complex enzymatic reactions from tryptophan and terpenoid precursors, ultimately accumulating in leaves at extremely low levels (usually less than 0.0005% of dry weight). This low content makes direct extraction from plants expensive and significantly influenced by factors such as geography and climate.
The traditional extraction and separation process usually includes the following steps: first, the dried Changchun flower leaves are crushed and extracted with organic solvents such as methanol and ethanol; Subsequently, alkaloids were enriched through preliminary purification steps such as acid-base treatment and liquid-liquid distribution; Finally, column chromatography techniques (such as alumina columns, silica gel columns) and high-performance liquid chromatography (HPLC) are used for fine separation to obtain high-purity vinblastine. Due to the limitations of plant extraction, semi synthetic routes have become an important supplement: using precursor substances with relatively high content in plants (such as Changchun Duoling and Wenduoling) as raw materials, coupling is carried out through chemical or enzymatic catalytic methods to efficiently prepare Changchun alkaloid. In addition, plant cell culture and synthetic biology techniques, such as utilizing microbial chassis cells to reconstruct biosynthetic pathways, are currently hot research topics aimed at achieving sustainable and controllable production of these high-value natural products.
Pharmacological activity research
The core pharmacological activity of vinblastine sulfate is its strong anti-tumor effect. As a M-phase cycle specific drug, it exhibits highly selective toxicity towards rapidly proliferating tumor cells.
1. Antitumor spectrum:
Vinblastine sulfate has shown significant therapeutic effects on various hematological malignancies and solid tumors. It is a classic drug for treating Hodgkin's lymphoma and non Hodgkin's lymphoma, often combined with other drugs such as doxorubicin, bleomycin, dacarbazine to form ABVD and other combination chemotherapy regimens, with definite efficacy. It is also an important choice in the treatment of testicular germ cell tumors, choriocarcinoma, breast cancer, Kaposi's sarcoma and other diseases. Its therapeutic effect on leukemia is closely related to the multi-target mechanism mentioned later.
2. Cytotoxicity and cell cycle arrest:
Vinblastine sulfate inhibits microtubule polymerization, disrupts spindle formation, and blocks the cell cycle in the metaphase of mitosis (M phase). This blockade ultimately triggers the cell apoptosis signaling pathway. In addition to this classic effect, research has also found that it has inhibitory effects on neuronal nicotinic acetylcholine receptors (nAChR), with a half maximal inhibitory concentration (IC50) of 8.9 μ M. This may be related to some of its neurological side effects, but also suggests its potential research value in non cancer fields such as neuropathic pain.
Mechanism of action and molecular targets
Vinblastine sulfate was initially recognized as a classic anti microtubule agent, but in-depth research on its use in the treatment of leukemia and other diseases has shown that its mechanism of action goes far beyond this, exhibiting characteristics of multi-target and networked regulation.
1. Core mechanism: Anti microtubule effect
Sulfate vinblastine specifically binds to the "vinblastine binding site" of microtubules, inhibiting microtubule polymerization and promoting microtubule depolymerization. This disrupts the dynamic balance of the mitotic spindle, leading to the inability of chromosomes to separate normally, thereby activating the spindle assembly checkpoint, causing cell cycle arrest and subsequent apoptosis.
2. Multi target regulatory network in leukemia treatment:
Recent studies have shown that vinblastine sulfate can affect a series of key signaling pathways and targets in leukemia cells, which may be the basis for overcoming drug resistance and enhancing therapeutic efficacy
* Apoptosis regulatory targets: It can downregulate the expression of anti apoptotic proteins Bcl-2 and Mcl-1, and may also affect pro survival signals, thereby reducing the apoptosis threshold of tumor cells.
* Metabolic and stress pathways: By activating the AMPK (PRKAA1) pathway, regulating cellular energy metabolism and inhibiting tumor growth. Regulation of the NFE2L2 (NRF2) pathway may affect cellular oxidative stress response.
* Epigenetics and signal transduction: The potential impact on SIRT1 (deacetylase) and inhibition of key oncogenic signaling pathways such as STAT3 and NOTCH1 can interfere with the survival, proliferation, and differentiation of leukemia cells at multiple levels.
* Other targets: The possible indirect effects on IDH1 (isocitrate dehydrogenase 1) mutant leukemia and the interaction with microtubule associated protein Tau (MAPT) have expanded the dimensions of its mechanism of action. Although it does not directly act on topoisomerase I (TOP1), it may produce synergistic effects in combination therapy.
This multi-target characteristic means that vinblastine sulfate can not only directly kill tumor cells through cytotoxic effects, but also regulate the tumor microenvironment and intracellular signaling network, with the potential for "one drug, multiple effects".
Evaluation of drug properties and pharmacokinetics
The pharmacological characteristics of vinblastine sulfate coexist, and its pharmacokinetic behavior is complex with significant individual differences.
1. Absorption, distribution, metabolism, and excretion (ADME):
* Absorption: Oral bioavailability is extremely low and unstable, so intravenous administration is strictly used in clinical practice.
* Distribution: After intravenous administration, it can quickly distribute to various tissues throughout the body, but has a high binding rate with plasma proteins. Its low blood-brain barrier permeability limits its application in central nervous system tumors.
* Metabolism: Mainly metabolized extensively in the liver through the cytochrome P450 enzyme system, especially CYP3A4. There are numerous metabolites, some of which are still active. The strong correlation with CYP3A4 means that its blood drug concentration is susceptible to the influence of enzyme inducers (such as rifampicin, phenytoin) or inhibitors (such as ketoconazole, clarithromycin), leading to decreased efficacy or increased toxicity.
* Excretion: The main route of excretion of the prototype drug is through bile and feces, with only a small amount (<5%) excreted through the kidneys and urine.
2. Challenges and optimization of drug formulation:
The main challenges lie in poor water solubility, narrow treatment window (effective dose close to toxic dose), and multidrug resistance (MDR) mediated by efflux pumps such as P-glycoprotein (P-gp). To overcome these limitations, researchers have developed novel delivery systems such as liposomes (such as vinblastine sulfate liposomes). Liposomal formulations can prolong the time of drugs in the bloodstream, selectively accumulate in tumor tissues through enhanced permeability and retention (EPR) effects, while reducing exposure to normal tissues, thereby improving efficacy while reducing side effects such as bone marrow suppression and neurotoxicity.
Clinical application prospects and prospects
Although vinblastine sulfate has been clinically used for more than half a century, its vitality is still strong, and its future development revolves around the following aspects:
1. Optimization of combination therapy strategy:
* Combination with traditional chemotherapy drugs: Continue to optimize its dosage and timing in classic protocols such as ABVD to balance efficacy and toxicity.
* Combination with targeted drugs: Based on its multi-target characteristics, the combination of BCL-2 inhibitors (such as Vinaclat), NOTCH inhibitors, STAT3 inhibitors and other targeted drugs is a highly promising direction for the treatment of recurrent/refractory leukemia and other diseases.
* Combined with immunotherapy: Chemotherapy drugs can induce immunogenic cell death and enhance tumor antigen exposure. Exploring the synergistic effect of vinblastine sulfate and immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) is currently one of the research hotspots in tumor immunotherapy.
2. Development of new formulations and drug delivery technologies:
In addition to liposomes, new delivery systems such as nanocrystals and albumin bound nanoparticles are being studied to further enhance tumor targeting, overcome drug resistance, and improve pharmacokinetic properties. Local administration (such as thoracic perfusion therapy for malignant pleural effusion) is also an application exploration to reduce systemic toxicity.
3. Expansion of indications and precision medicine:
In depth exploration of its multi-target mechanism may provide theoretical basis for its application in non cancer diseases such as autoimmune diseases and certain proliferative skin diseases. At the same time, screening the most likely patient population to benefit through biomarkers (such as specific gene mutations, protein expression profiles) and achieving personalized precision medication is the key to improving its treatment index.
4. Breakthroughs in green and sustainable production technologies:
By utilizing synthetic biology techniques to reconstruct and optimize the biosynthetic pathway of vinblastine in microorganisms such as yeast, it is expected to completely eliminate dependence on plant resources, achieve low-cost, high-efficiency, and environmentally friendly industrial production, and ensure stable supply of drugs.
Conclusion
As a successful example of natural product drug development, vinblastine sulfate has a history spanning over half a century and still plays an irreplaceable role in the global fight against cancer. From the initial understanding of a single "microtubule inhibitor" to today's in-depth understanding of its complex multi-target action network, the development of science has continuously endowed this classic drug with new connotations. Despite facing challenges such as water solubility, drug resistance, and toxicity, the potential application of vinblastine sulfate is expected to be further explored through novel delivery systems, rational combination therapy strategies, and innovative synthetic biology production technologies. It is not only the backbone of past and present anti-cancer chemotherapy, but also connects future more precise, efficient, and low toxicity tumor treatment models through continuous scientific research. The in-depth study of vinblastine sulfate will continue to provide valuable insights and impetus for natural product medicinal chemistry, tumor pharmacology, and translational medicine.
